Astrocytoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Glioma (540)

Anaplastic Astrocytoma (13)

Glioma (540)

Anaplastic Astrocytoma (13)

›

No biomarker	Astrocytoma	No biomarker	Astrocytoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2	cobimetinib Sensitive: A2 - Guideline cobimetinib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	thioguanine Sensitive: A2 - Guideline thioguanine Sensitive : A2	thioguanine Sensitive: A2 - Guideline thioguanine Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carboplatin + vincristine Sensitive: A2 - Guideline carboplatin + vincristine Sensitive : A2	carboplatin + vincristine Sensitive: A2 - Guideline carboplatin + vincristine Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2

Astrocytoma

Associations(74)

Associations
(74)